BLA 761136 · Celgene Corp
Reblozyl
Luspatercept-Aamt · Subcutaneous · Erythroid Maturation Agent
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Nov 8, 2019
Approved uses
3
Original approval plus efficacy supplements
Registered trials
57
12 Phase 3, 20 recruiting
FAERS reports
2,614
1,604 serious, 414 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 20, 2026.
REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions ( 1.2 ). • Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) ( 1.3 ). • Limitations of Use: REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.4 ). 1.1 Beta Thalassemia REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. 1.2 Myelodysplastic Syndromes Associated Anemia REBLOZYL is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions. 1.3 Myelodysplastic Syndromes with Ring Sideroblasts or Myelodysplastic/ Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis Associated Anemia REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts...
Mechanism: Luspatercept-aamt is a recombinant fusion protein that binds several endogenous TGF-β superfamily ligands, thereby diminishing Smad2/3 signaling. In models of β-thalassemia and MDS, luspatercept-aamt decreased abnormally elevated Smad2/3 signaling and improved hematology parameters associated with ineffective erythropoiesis in mice. Luspatercept-aamt promoted erythroid maturation through differentiation and increasing the percentage of late-stage erythroid precursors (normoblasts) in the bone marrow of mice and increased erythroid precursors in humans, thereby increasing erythropoiesis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 28, 2023 Supplement 9 · Efficacy · priority review OrphanLabelLetter
- Apr 3, 2020 Original approval · Efficacy NovelOrphanLabelLetterReview
- Nov 8, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
- REBLOZYL · LUSPATERCEPT-AAMT 75MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
- REBLOZYL · LUSPATERCEPT-AAMT 25MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Luspatercept" as an intervention, any sponsor and status, largest first.
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsPivotal-lookingRecruiting
CelgeneBristol Myers Squibb (BMY)
NCT04064060 · 665 participants (planned) · Start Aug 12, 2019 · Primary completion May 12, 2028
Drug: Luspatercept · For: Myelodysplastic Syndromes (MDS); Beta-thalassemia; Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Sites: Los Angeles, California; Oakland, California; Stanford, California · 143 sites in all
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05949684 · 402 participants · Start Oct 24, 2023 · Primary completion Mar 24, 2028
Drug: Luspatercept; Epoetin Alfa · For: Myelodysplastic Syndromes
Sites: Clovis, California; Fountain Valley, California; Los Alamitos, California · 144 sites in all
- A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïvePivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT03682536 · 363 participants · Start Jan 2, 2019 · Primary completion Mar 31, 2023
Drug: Luspatercept; Epoetin alfa · For: Myelodysplastic Syndromes
Sites: Berkeley, California; San Diego, California; Whittier, California · 226 sites in all
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) ThalassemiaPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02604433 · 336 participants · Start May 2, 2016 · Primary completion Jan 5, 2021
Drug: Luspatercept · For: Erythrocyte Transfusion; Beta-Thalassemia
Sites: Los Angeles, California; Oakland, California; Chicago, Illinois · 76 sites in all
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsPivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT04717414 · 313 participants · Start Feb 25, 2021 · Primary completion May 26, 2025
Drug: ACE-536 · For: Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis and 2 more
Sites: Los Angeles, California; Orlando, Florida; Plantation, Florida · 185 sites in all
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)Pivotal-lookingNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07463820 · 270 participants (planned) · Start Dec 18, 2026 · Primary completion Dec 31, 2027
Drug: Emavusertib; Epoetin Alfa and 1 more · For: Myelodysplastic Syndrome
- A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02631070 · 229 participants · Start Feb 9, 2016 · Primary completion Jun 18, 2019
Drug: Luspatercept · For: Myelodysplastic Syndromes
Sites: Stanford, California; New Haven, Connecticut; Tampa, Florida · 74 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death244
- off label use193
- haemoglobin decreased144
- fatigue137
- drug ineffective114
- weight decreased92
- product storage error85
- dizziness84
- myelodysplastic syndrome75
- dyspnoea73
- fall70
- asthenia57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 142 |
| 2021 | 248 |
| 2022 | 440 |
| 2023 | 325 |
| 2024 | 494 |
| 2025 | 536 |
| 2026 | 424 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Reblozyl (Luspatercept-Aamt)
2024 spending
$40.6M
Beneficiaries
402
3,028 claims
Per beneficiary
$101,095
$8,552.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,550,369 |
| 2021 | $16,465,063 |
| 2022 | $19,913,471 |
| 2023 | $26,119,753 |
| 2024 | $40,640,022 |
Part B: Reblozyl (Luspatercept-Aamt) · HCPCS J0896
2024 spending
$755M
Beneficiaries
6,466
46,355 claims
Per beneficiary
$116,808
2024 ASP limit $40.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $108,401,652 |
| 2021 | $266,191,359 |
| 2022 | $332,954,781 |
| 2023 | $451,098,388 |
| 2024 | $755,278,437 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
Della Porta MG, Garcia-Manero G, Santini V, et al. · Lancet Haematol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis.
Alhajahjeh A, Woite NL, Rolles B, et al. · Blood Adv 2025 · Systematic Review, Meta-Analysis
- Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study.
Taher AT, Viprakasit V, Kattamis A, et al. · Blood Adv 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.